Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market CAGR Outlook And Future Development
The single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market has shown robust expansion in its size during recent years. This market is expected to increase from $6.53 billion in 2025 to $7.04 billion in 2026, registering a compound annual growth rate (CAGR) of 7.9%. Historically, this growth has been driven by the rising prevalence of cancer and cardiovascular diseases, the expansion of nuclear medicine infrastructure, a growing demand for functional imaging techniques, advancements in radiopharmaceutical development, and the proliferation of diagnostic imaging centers.
The market for single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceuticals is projected to experience substantial expansion over the upcoming years, with an anticipated growth to $9.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. Key factors driving this expansion during the projection period include a rising need for individualized diagnostic approaches, the proliferation of theranostics applications, increased funding into nuclear medicine research, technological improvements in radioisotope manufacturing, and the broader integration of PET imaging in clinical settings. Significant trends expected in this timeframe encompass the greater acceptance of targeted radiopharmaceuticals for specific disease visualization, a surging preference for hybrid imaging methods that merge SPECT and PET technologies, the expanded utilization of isotopes with short half-lives to enhance safety and imaging accuracy, the broadening scope of radiopharmaceutical applications within oncology and neurology, and a heightened emphasis on prompt disease identification and functional imaging.
Get A Free Sample Report With In-Depth Market Insights:
Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Development Factors: What’s Supporting Demand?
The increasing incidence of cancer is projected to stimulate the expansion of the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market. Cancer, defined by the unregulated multiplication and dissemination of abnormal cells leading to tumor formation and impaired bodily functions, is seeing a rise in prevalence, largely attributable to an aging demographic more prone to genetic mutations that initiate uncontrolled cell division. SPECT and PET radiopharmaceuticals offer highly accurate and sensitive tumor imaging, aiding in early diagnosis, precise staging, therapy tracking, and tailoring personalized treatment plans. For example, the World Health Organization, an international body based in Switzerland, reported in February 2024 a forecast of over 35 million new cancer cases by 2050, marking a 77% rise from the approximately 20 million cases in 2022. Consequently, the growing occurrence of cancer is a key factor propelling the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market forward.
Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Segment Analysis: What Are The Core Market Categories?
The single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market covered in this report is segmented –
1) By Type Of Radiopharmaceuticals: Single Photon Emission Computed Tomography, Positron Emission Tomography
2) By Radioisotope Type: Technetium-99m, Fluorine-18, Iodine-123, Gallium-68
3) By Route Of Administration: Injectable, Inhalation, Oral
4) By Application Areas: Oncology, Cardiology, Neurology, Other Application Areas
5) By End User: Hospitals, Diagnostic Imaging Centers, Research Institutions, Other End Users
Subsegments:
1) By Single Photon Emission Computed Tomography: Cardiac Imaging Agents, Bone Imaging Agents, Renal Imaging Agents, Pulmonary Imaging Agents, Thyroid Imaging Agents
2) By Positron Emission Tomography: Oncology Imaging Agents, Neurology Imaging Agents, Cardiology Imaging Agents, Infection And Inflammation Imaging Agents, Metabolic Imaging Agents
Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Transformation Trends: What Innovations Are Driving Change?
Leading firms within the positron emission tomography (PET) radiopharmaceutical market are concentrating efforts on creating novel products, specifically cardiac positron emission tomography (PET) tracers, to enhance the precision and availability of diagnostic imaging for coronary artery disease. These cardiac positron emission tomography (PET) tracers are radioactive substances employed in PET imaging for visualizing blood flow and identifying regions of diminished perfusion within the heart, thereby assisting clinicians in precisely diagnosing coronary artery disease and evaluating myocardial ischemia and infarction through a noninvasive and exceptionally sensitive method. An example of this is when, in September 2024, GE HealthCare, a U.S.-based entity specializing in medical technology and pharmaceutical diagnostics, secured U. S. Food and Drug Administration (FDA) approval for Flyrcado (flurpiridaz F 18). This product functions as a cardiac PET (positron emission tomography) tracer intended for myocardial perfusion imaging (MPI) in individuals diagnosed with or suspected of having coronary artery disease. Flyrcado itself is a convenient, ready-to-use unit dose radiotracer featuring a prolonged half-life of 109 minutes. This characteristic allows for high-resolution PET imaging, exercise stress testing, and repeat scans within the same session, which in turn boosts diagnostic accuracy when contrasted with conventional SPECT MPI agents. The aforementioned approval broadens accessibility to advanced cardiac PET imaging, providing significant advantages especially for patients challenging to image, including women and individuals with a high body mass index (BMI).
Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Leading Companies And Competitive Benchmarking
Major companies operating in the single photon emission computed tomography (spect) or positron emission tomography (pet) radiopharmaceutical market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies Inc., Bracco Imaging S. p. A., Lantheus Holdings Inc., Jubilant Pharmova Limited, Curium Pharma, Sofie Biosciences Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler SE, Advanced Accelerator Applications S. A., Nordion Inc., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, Eczacibasi-Monrol Nuclear Products, Radioisotope Centre POLATOM, IBA Radiopharma Solutions, Dongcheng, Pars Isotope Company
View The Full Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Report:
Single Photon Emission Computed Tomography (SPECT) Or Positron Emission Tomography (PET) Radiopharmaceutical Market Top Region By Revenue And Market Share
North America was the largest region in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single photon emission computed tomography (SPECT) or positron emission tomography (PET) radiopharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
